alagebrium has been researched along with alt-946 in 2 studies
| Studies (alagebrium) | Trials (alagebrium) | Recent Studies (post-2010) (alagebrium) | Studies (alt-946) | Trials (alt-946) | Recent Studies (post-2010) (alt-946) |
|---|---|---|---|---|---|
| 83 | 10 | 31 | 5 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawakami, M; Kuroki, M | 1 |
| Allen, TJ; Jandeleit-Dahm, KA; Lassila, M | 1 |
2 review(s) available for alagebrium and alt-946
| Article | Year |
|---|---|
[Aminoguanidine and other AGE inhibitors].
Topics: Amides; Animals; Arteriosclerosis; Cardiovascular Diseases; Cataract; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Retinopathy; Disease Models, Animal; Drug Design; Glycation End Products, Advanced; Guanidines; Humans; Hydrazines; Hypoglycemic Agents; Thiadiazoles; Thiazoles; Thiazolidines | 2002 |
Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies.
Topics: Amides; Animals; Arteriosclerosis; Diabetic Angiopathies; Diabetic Nephropathies; Glycation End Products, Advanced; Humans; Hydrazines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles | 2005 |